Stay updated on Talazoparib in BRCA+ Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Talazoparib in BRCA+ Breast Cancer Clinical Trial page.

Latest updates to the Talazoparib in BRCA+ Breast Cancer Clinical Trial page
- Check7 days agoChange DetectedThe study record page now shows a 403 Forbidden error with a minimal header and a Home link, replacing the previous EMBRACA trial details.SummaryDifference16%

- Check14 days agoChange DetectedRevision label updated from v3.6.6 to v3.7.0, indicating a newer site build. This reflects an underlying update to the page's code or assets rather than changes to study content.SummaryDifference0.0%

- Check21 days agoChange DetectedTel Litwinsky, Israel was added to the EMBRACA study locations. Qiryat Krinitzi, Israel was removed from the locations list.SummaryDifference0.1%

- Check28 days agoChange DetectedTel Litwinsky, Israel, 5265601 was removed and Qiryat Krinitzi, Israel, 5265601 was added to the study's locations list. The page revision was updated from v3.6.5 to v3.6.6.SummaryDifference0.1%

- Check49 days agoChange DetectedThe page's revision tag was updated from Revision: v3.6.4 to Revision: v3.6.5, reflecting a new version of the page.SummaryDifference0.0%

- Check70 days agoChange DetectedThe page’s revision version updated from v3.6.3 to v3.6.4, indicating a small backend/template update rather than changes to visible content.SummaryDifference0.0%

Stay in the know with updates to Talazoparib in BRCA+ Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Talazoparib in BRCA+ Breast Cancer Clinical Trial page.